Zobrazeno 31 - 40
of 111
pro vyhledávání: '"Andy Ni"'
Autor:
Matthew D. Hellmann, Helena Yu, Gregory J. Riely, Marc Ladanyi, Maria E. Arcila, Nikolaus Schultz, Charles M. Rudin, Mark G. Kris, Alexander Drilon, Bob T. Li, Francisco Sanchez-Vega, Andy Ni, Megan Tenet, Hira Rizvi, Michael Offin
Univariate and multivariate analysis of TTD and OS by median TMB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab11361e3a1ea56aab371d314175d63f
https://doi.org/10.1158/1078-0432.22469042.v1
https://doi.org/10.1158/1078-0432.22469042.v1
Autor:
Xiaohan Guo, Takashi Yamashiro, Chihiro Tanikawa, Toru Deguchi, Andy Ni, Shimizu Yujin, Yohei Kera, Koji Fujiyama
Publikováno v:
American Journal of Orthodontics and Dentofacial Orthopedics. 161:542-547
Introduction The use of aligner therapy for orthodontic treatment has increased substantially in the past decade. However, no study has compared treatment outcomes between the conventional fixed appliance and Invisalign therapies in patients with a s
Autor:
Brennan Skulski, Allen R. Firestone, Fonda G. Robinson, Andy Ni, Henry W. Fields, David J. Heinlein, Alexander R Desman
Publikováno v:
American Journal of Orthodontics and Dentofacial Orthopedics. 161:e114-e126
The purpose of this study was to determine if written rehearsal of informed consent improved 6-month recall and comprehension compared with the current best practices.A consultation was provided and subjects read the modified informed consent documen
Autor:
Jasmine S. Sukumar, Sagar Sardesai, Andy Ni, Nicole Williams, Bhuvaneswari Ramaswamy, Robert Wesolowski, Mathew A. Cherian, Daniel Stover, Margaret Gatti-Mays, Ashley C. Pariser, Preeti K. Sudheendra, Mridula A. George, maryam lustberg
Publikováno v:
Cancer Research. 83:P1-02
Background: Approximately 10% of breast cancers (BC) are hormone receptor positive (HR+) and HER2 positive (HER2+). Despite treatment advances in the modern era of HER2 targeted therapies for early-stage disease, there remains a risk for late relapse
Publikováno v:
American Journal of Orthodontics and Dentofacial Orthopedics. 160:718-724
Introduction This study aimed to establish if there is a significant difference in effectiveness between 2 generations of Invisalign trays in terms of Peer Assessment Rating (PAR) score reduction for finished patients from a graduate orthodontic clin
Publikováno v:
Journal of Oral and Maxillofacial Surgery. 80:S57-S58
Autor:
Koji Fujijyama, Yohei Kera, Shimizu Yujin, Chihiro Tanikawa, Takashi Yamashiro, Xiaohan Guo, Andy Ni, Toru Deguchi
Publikováno v:
American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics. 163(1)
Autor:
Thaís Fischer, Andy Ni, Kurt S. Bantilan, Jacob D. Soumerai, Anna Alperovich, Connie Batlevi, Anas Younes, Andrew D. Zelenetz
Publikováno v:
Leukemialymphoma. 63(3)
Although treatment with anti-CD20 monoclonal antibodies (mAb) has improved outcomes in B-cell malignancies, it's associated with increased risk of hypogammaglobulinemia (HG). Our study aimed to determine the effects of anti-CD20 mAb on serum immunogl
Autor:
Yosef Tobi, Neal Rosen, Amanda Johnson, Michelle S. Ginsberg, Alyssa Shannon, Eusebio Manchado, Charles M. Rudin, Victoria Perron, Mark G. Kris, Gregory J Riely, Piro Lito, Andy Ni, Kathryn C. Arbour, Matthew J. Bott, Helena A. Yu, Andrei I. Holodny, Linda Ahn, Scott W. Lowe, Marc Ladanyi
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100256-(2022)
Introduction: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a mechanism of trametinib resist
Autor:
Kurt S. Bantilan, Anna Alperovich, Anas Younes, Jacob D. Soumerai, Amanda R Copeland, Zhitao Ying, Katy Smith, Andy Ni, Thais Fischer, Connie Lee Batlevi, Andrew D. Zelenetz
Publikováno v:
Leuk Lymphoma
It is difficult to demonstrate an overall survival (OS) benefit in trials of immediate therapy vs observation in follicular lymphoma (FL). Time to 2(nd) treatment (TT2T) may be a preferred endpoint. We identified 584 consecutive patients at our insti